Announcements Trials

Browse Landscape

Phase

Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 437 Breast Neoplasms 382 Neoplasms 291 Prostatic Neoplasms 195 Neoplasm Metastasis 155 Multiple Myeloma 148 Colorectal Neoplasms 124 Lung Neoplasms 105 Ovarian Neoplasms 102 Parkinson Disease 4, Autosomal Dominant Lewy Body 98 Melanoma 95 Lymphoma, Follicular 94 Recurrence 89 Lymphoma, Non-Hodgkin 82 Papillomavirus Infections 81 Leukemia, Lymphocytic, Chronic, B-Cell 81 Carcinoma, Hepatocellular 81 Stomach Neoplasms 76 Small Cell Lung Carcinoma 73 Leukemia, Myeloid, Acute 70 Pancreatic Neoplasms 67 Pain 66 Carcinoma, Renal Cell 65 Uterine Cervical Neoplasms 64 Keratosis, Actinic 63 Urinary Bladder Neoplasms 59 Lymphoma, Large B-Cell, Diffuse 53 Myasthenia Gravis 52 Leiomyoma 49 Carcinoma 49

Interventions

olverembatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × INDUSTRY × GIST × Clear all

NCT06640361 2024-12-27

A Study of Olverembatinib in SDH-deficient GIST.

Ascentage Pharma Group Inc.

Phase 3 Recruiting

GIST

Data powered by HemOnc (CC BY 4.0) Colophon ⚡